RxDoctor Payments Data

Aaron Katz, MD

Urology · Garden City, NYNPI 1740399922

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $13,500 of the $19,242 with a category attached, or 70.2%. Boston Scientific accounts for 82.4% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2023 at $14,912 and has fallen 94.6% since, to $799 in 2025.

$19,242in general payments, 2019–2025

Across 73 payments — averaging $263.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$16K
  • Procept Biorobotics Corporation$1K
  • Palette Life Sciences, Inc.$719
  • Teleflex LLC$245
  • Coloplast$211
  • Pfizer$143
  • plus $859 from 12 others
$71,841in research payments, 2019–2025

Across 11 payments — averaging $6531.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bayer$51K
  • Astellas Pharma Global Development$21K

What the payments were for

  • Consulting fees$13,50070%
  • Travel & lodging$1,4257%
  • Food & beverage$4,21822%
  • Education$1001%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,242 in reported general payments places this provider in the 85th percentile of 952 urology providers in New York.

See all urology providers in New York →

Medicare billing

Part B allowed, 2024
$463,464
Medicare patients
878
Services billed
2,127

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron26$13,477
Silodosin115$13,211
Solifenacin Succinate99$8,402
Tamsulosin Hcl378$5,032
Finasteride328$3,813
Tadalafil32$3,192
Dutasteride68$1,991
Bicalutamide66$1,620
Alfuzosin Hcl ErAlfuzosin Hcl70$1,256
Oxybutynin Chloride ErOxybutynin Chloride22$300
Sildenafil Citrate16$187
Levofloxacin29$185
Cefdinir20$122
Metformin Hcl ErMetformin Hcl12$101
Oxybutynin Chloride16$94

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$141$13,47726 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 952 urology providers in New York.

Other urology in Garden City

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →